Furthermore, MAPK hyperactivation is a hallmark of IBC patient tumors, which is recapitulated in our preclinical model of drug resistance with sustained pERK levels despite suppression of pEGFR by the EGFR-TKI (Lapatinib) treatment (Fig. 7b). This evidence concerns the gene EGFR and inflammatory breast carcinoma.